# Conatumumab, Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

> **NCT01017822** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Radiation Therapy Oncology Group**

## Conditions studied

- Pancreatic Cancer

## Interventions

- **BIOLOGICAL:** conatumumab
- **DRUG:** capecitabine
- **DRUG:** gemcitabine hydrochloride
- **RADIATION:** 3-dimensional conformal radiation therapy

## Key facts

- **NCT ID:** NCT01017822
- **Lead sponsor:** Radiation Therapy Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This study was withdrawn due to study agent availability.
- **Last updated:** 2013-06-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01017822

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01017822, "Conatumumab, Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01017822. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*